We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2009;169(18):1648. doi:10.1001/archinternmed.2009.331.
Text Size: A A A
Published online

Major depression has been associated with coronary heart disease, but the mechanisms are unclear. Coronary microvascular disease represents a proatherosclerotic state with substantial prognostic value. This study examined whether depression affects coronary microvascular function. Middle-aged, predominantly healthy male twins underwent myocardial perfusion imaging with positron emission tomography and myocardial blood flow quantitation and measurement of coronary flow reserve in response to adenosine, a measure of overall coronary vasodilator capacity. The results indicate a relation between depression and coronary microvascular dysfunction that is largely due to a shared genetic substrate. These data suggest that common pathophysiological processes link depression and early atherosclerosis.

Glucocorticoid use is associated with cardiovascular disease, but data are limited on the risk of atrial fibrillation or flutter (AF/FL). Christiansen et al examined the impact of systemic glucocorticoid use on the risk of AF/FL in a large, population-based case-control study including 20 221 patients with AF/FL and 202 130 controls. Current glucocorticoid use was associated with increased risk of AF/FL (adjusted odds ratio [OR], 1.92; 95% confidence interval [CI], 1.79-2.06) compared with never use, and the association was even stronger in new users (adjusted OR, 3.62; 95% CI, 3.11-4.22). The increased risk remained robust in patients with and without pulmonary and cardiovascular diseases. Former glucocorticoid use was not associated with an increased risk of AF/FL (adjusted OR, 1.00; 95% CI, 0.96-1.06). Physicians should be aware of the almost 2-fold increased risk of AF/FL in glucocorticoid users.

The neighborhood people live in might play a role in their risk of developing type 2 diabetes mellitus (T2DM). Auchincloss et al examined whether neighborhood resources that support being physically active and having a healthy diet are associated with incidence of T2DM during 5 years of follow-up in a large and diverse population-based sample. The authors found that residents of neighborhoods with more favorable resources had lower T2DM incidence. Findings from this study are consistent with the hypotheses that improving neighborhood features such as having nearby, pleasant, safe destinations to walk to and improving the availability of healthy foods may be viable population-level strategies for addressing T2DM.

Intimate partner violence (IPV) affects as many as 4 in 10 women during their lifetime. This study characterized the relative risk of clinically identified diagnoses in women aged 18 to 64 with a past-year history of IPV (n = 242) compared with never-abused women (n = 1686). Compared with never-abused women, women with a history of IPV in the past year had a pronounced increased risk of receiving psychosocial/mental health diagnoses—with an almost 6-fold increase in risk of clinically identified substance abuse and nearly 5-fold increase in family and social problems, a 3-fold increase in depression, and a 2-fold increase in anxiety/neuroses and tobacco use. Abused women also had a more than 3-fold increase in risk of receiving a diagnosis of sexually transmitted disease, as well as significantly increased risk of headaches, contusions/abrasions, lacerations, abdominal pain, urinary tract infections, chest pain, and numerous diagnoses within the category of musculoskeletal conditions.

Menopausal estrogen plus progestin therapy is associated with both increased incidence of breast tenderness and increased risk of breast cancer. This study analyzed data from participants of the Women's Health Initiative Estrogen plus Progestin Clinical Trial, a randomized trial of daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, or placebo in postmenopausal women. Breast tenderness was reported on questionnaires at baseline and at 12 months, and breast cancer incidence was recorded for an average of 5.6 years. Among the women who were assigned to active treatment, those who reported the new onset of breast tenderness (NOBT) at the 12-month follow-up visit had approximately a 1.5-fold increased risk of breast cancer compared with women who did not have NOBT at the 12-month follow-up visit. The authors conclude that NOBT during the use of conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, may identify women at elevated breast cancer risk.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.